Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Effects of Onyx-015 among metastatic colorectal cancer patients that have failed prior treatment with 5-FU/leucovorin

Cancer Gene Therapy volume 12, pages 673–681 (2005)Cite this article

Abstract

Despite recent improvements in the treatment of metastatic colorectal cancer, few patients are cured and the response rates to second-line treatments are poor. Onyx-015, an oncolytic virus, was administered to patients with metastatic colorectal cancer by hepatic artery infusion. No dose-limiting toxicities were observed in the phase I/II studies. Onyx-015 can kill tumor cells by mechanisms that are distinct from chemotherapeutic agents and may therefore have activity among patients who have failed first-line chemotherapy. The 24 patients included in this analysis had failed first-line therapy with 5-FU/leucovorin, 79% of the patients failed two or more regimens and 58% had failed treatment with Irinotecan. Despite the extensive prior therapy, the median survival of these patients was 10.7 months, 46% were alive at 1 year and two patients (8%) had partial responses. In all, 11 patients (46%) had stable disease at the completion of the four planned viral treatments (3 months). The median survival of this group of patients was 19 months, suggesting that stable disease may be an important predictor of benefit with oncolytic viruses. Eight of the 11 patients with stable disease at 3 months demonstrated a unique radiographic pattern of transient enlargement of tumor masses (10–48%) after the initial infusions of Onyx-015, followed by radiographic evidence of extensive tumor necrosis and regression. The initial enlargement and subsequent tumor necrosis resulted in a prolonged time to achieve objective tumor regression. In addition, the transient enlargement of the tumor masses may have resulted in premature removal of responding patients. Treatment of eight patients was stopped prior to completion of the planned four treatments due to presumed progression as defined by standard radiographic criteria (>25% increase in tumor size). Functional imaging, such as positron emission tomography (PET) scans, may help distinguish clinical responses from progressive disease following treatment with oncolytic viruses. Onyx-015 may benefit patients with refractory colorectal cancer and additional studies that include PET scans to assess clinical response are warranted.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  1. Greenlee RT, Murray T, Bolden S, Wingo PA . Cancer statistics, 2000. CA Cancer J Clin. 2000;50:7–33.

    Article  CAS  PubMed  Google Scholar 

  2. Rothenberg ML . Efficacy of oxaliplatin in the treatment of colorectal cancer. Oncology (Huntingt). 2000;14:9–14.

    CAS  Google Scholar 

  3. Rothenberg ML, Oza AM, Bigelow RH, et al. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol. 2003;21:2059–2069.

    Article  CAS  PubMed  Google Scholar 

  4. Saltz LB . The role of irinotecan in colorectal cancer. Curr Oncol Rep. 1999;1:155–160.

    Article  CAS  PubMed  Google Scholar 

  5. Zeuli M, Nardoni C, Pino MS, et al. Phase II study of capecitabine and oxaliplatin as first-line treatment in advanced colorectal cancer. Ann Oncol. 2003;14:1378–1382.

    Article  CAS  PubMed  Google Scholar 

  6. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol. 2003;21:60–65.

    Article  CAS  PubMed  Google Scholar 

  7. Lavery IC, Lopez-Kostner F, Pelley RJ, Fine RM . Treatment of colon and rectal cancer. Surg Clin North Am. 2000;80:535–569.

    Article  CAS  PubMed  Google Scholar 

  8. Saltz LB, Meropol NJ, Loehrer Sr PJ, Needle MN, Kopit J, Mayer RJ . Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol. 2004;22:1201–1208.

    Article  CAS  PubMed  Google Scholar 

  9. Motzer RJ, Amato R, Todd M, et al. Phase II trial of antiepidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinoma. Invest New Drugs. 2003;21:99–101.

    Article  CAS  PubMed  Google Scholar 

  10. Rougier P, Van Cutsem E, Bajetta E, et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet. 1998;352:1407–1412.

    Article  CAS  PubMed  Google Scholar 

  11. Rougier P, Bugat R, Douillard JY, et al. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol. 1997;15:251–260.

    Article  CAS  PubMed  Google Scholar 

  12. Falcone A, Cianci C, Pfanner E, et al. Continuous-infusion 5-fluorouracil in metastatic colorectal cancer patients pretreated with bolus 5-fluorouracil: clinical evidence of incomplete cross-resistance. Ann Oncol. 1994;5:291.

    Article  CAS  PubMed  Google Scholar 

  13. Falcone A, Allegrini G, Lencioni M, et al. Protracted continuous infusion of 5-fluorouracil and low-dose leucovorin in patients with metastatic colorectal cancer resistant to 5-fluorouracil bolus-based chemotherapy: a phase II study. Cancer Chemother Pharmacol. 1999;44:159–163.

    Article  CAS  PubMed  Google Scholar 

  14. Mori A, Bertoglio S, Guglielmi A, et al. Activity of continuous-infusion 5-fluorouracil in patients with advanced colorectal cancer clinically resistant to bolus 5-fluorouracil. Cancer Chemother Pharmacol. 1993;33:179–180.

    Article  CAS  PubMed  Google Scholar 

  15. Cunningham D, Glimelius B . A phase III study of irinotecan (CPT-11) versus best supportive care in patients with metastatic colorectal cancer who have failed 5-fluorouracil therapy. V301 Study Group. Semin Oncol. 1999;26:6–12.

    CAS  PubMed  Google Scholar 

  16. Sadahiro S, Suzuki T, Ishikawa K, et al. Recurrence patterns after curative resection of colorectal cancer in patients followed for a minimum of ten years. Hepatogastroenterology. 2003;50:1362–1366.

    PubMed  Google Scholar 

  17. Altendorf-Hofmann A, Scheele J . A critical review of the major indicators of prognosis after resection of hepatic metastases from colorectal carcinoma. Surg Oncol Clin N Am. 2003;12:165–192.

    Article  PubMed  Google Scholar 

  18. Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH . Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999;230:309–318 discussion 318–321.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Kemeny N, Huang Y, Cohen AM, et al. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med. 1999;341:2039–2048.

    Article  CAS  PubMed  Google Scholar 

  20. Kemeny N, Jarnagin W, Gonen M, et al. Phase I/II study of hepatic arterial therapy with floxuridine and dexamethasone in combination with intravenous irinotecan as adjuvant treatment after resection of hepatic metastases from colorectal cancer. J Clin Oncol. 2003;21:3303–3309.

    Article  CAS  PubMed  Google Scholar 

  21. Cohen AD, Kemeny NE . An update on hepatic arterial infusion chemotherapy for colorectal cancer. Oncologist. 2003;8:553–566.

    Article  PubMed  Google Scholar 

  22. Reid T, Galanis E, Abbruzzese J, et al. Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints. Cancer Res. 2002;62:6070–6079.

    CAS  PubMed  Google Scholar 

  23. Reid T, Galanis E, Abbruzzese J, et al. Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial. Gene Therapy. 2001;8:1618–1626.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Heise C, Sampson-Johannes A, Williams A, McCormick F, Von Hoff DD, Kirn DH . ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med. 1997;3:639–645.

    Article  CAS  PubMed  Google Scholar 

  25. McCormick F . ONYX-015 selectivity and the p14ARF pathway. Oncogene. 2000;19:6670–6672.

    Article  CAS  PubMed  Google Scholar 

  26. McCormick F . Cancer-specific viruses and the development of ONYX-015. Cancer Biol Ther. 2003;2:S157–S160.

    Article  CAS  PubMed  Google Scholar 

  27. Ries SJ, Brandts CH, Chung AS, et al. Loss of p14ARF in tumor cells facilitates replication of the adenovirus mutant dl1520 (ONYX-015). Nat Med. 2000;6:1128–1133.

    Article  CAS  PubMed  Google Scholar 

  28. Harada JN, Berk AJ . p53-Independent and -dependent requirements for E1B-55K in adenovirus type 5 replication. J Virol. 1999;73:5333–5344.

    CAS  PubMed  PubMed Central  Google Scholar 

  29. Martin ME, Berk AJ . Adenovirus E1B 55K represses p53 activation in vitro. J Virol. 1998;72:3146–3154.

    CAS  PubMed  PubMed Central  Google Scholar 

  30. Yew PR, Berk AJ . Inhibition of p53 transactivation required for transformation by adenovirus early 1B protein. Nature. 1992;357:82–85.

    Article  CAS  PubMed  Google Scholar 

  31. Kao CC, Yew PR, Berk AJ . Domains required for in vitro association between the cellular p53 and the adenovirus 2 E1B 55K proteins. Virology. 1990;179:806–814.

    Article  CAS  PubMed  Google Scholar 

  32. Yew PR, Kao CC, Berk AJ . Dissection of functional domains in the adenovirus 2 early 1B 55K polypeptide by suppressor-linker insertional mutagenesis. Virology. 1990;179:795–805.

    Article  CAS  PubMed  Google Scholar 

  33. Sze DY, Freeman SM, Slonim SM, et al. Dr Gary J Becker Young Investigator Award: intraarterial adenovirus for metastatic gastrointestinal cancer: activity, radiographic response, and survival. J Vasc Interv Radiol. 2003;14:279–290.

    Article  PubMed  Google Scholar 

  34. Reid TR, Sze DY . Developments in medical oncology and their implications for interventional radiology. Tech Vasc Interv Radiol. 2002;5:177–181.

    Article  PubMed  Google Scholar 

  35. Whiteford MH, Whiteford HM, Yee LF, et al. Usefulness of FDG-PET scan in the assessment of suspected metastatic or recurrent adenocarcinoma of the colon and rectum. Dis Colon Rectum. 2000;43:759–767 discussion 767–770.

    Article  CAS  PubMed  Google Scholar 

  36. Spaepen K, Stroobants S, Dupont P, et al. Early restaging positron emission tomography with (18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma. Ann Oncol. 2002;13:1356–1363.

    Article  CAS  PubMed  Google Scholar 

  37. Cerfolio RJ, Ojha B, Mukherjee S, Pask AH, Bass CS, Kotholi CR . Positron emission tomography scanning with 2-fluoro-2-deoxy-d-glucose as a predictor of response of neoadjuvant treatment for non-small cell carcinoma. J Thorac Cardiovasc Surg. 2003;125:938–944.

    Article  PubMed  Google Scholar 

  38. Libutti SK, Alexander Jr HR, Choyke P, et al. A prospective study of 2-[18F] fluoro-2-deoxy-D-glucose/positron emission tomography scan, 99mTc-labeled arcitumomab (CEA-scan), and blind second-look laparotomy for detecting colon cancer recurrence in patients with increasing carcinoembryonic antigen levels. Ann Surg Oncol. 2001;8:779–786.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Palo Alto Veteran's Administration Hospital and Stanford University, San Francisco, California, USA

    Tony R Reid & Daniel Y Sze

  2. Onyx Pharmaceuticals, San Francisco, California, USA

    Scott Freeman & Leonard Post

  3. University of California, San Francisco, California, USA

    Frank McCormick

Authors
  1. Tony R Reid
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Scott Freeman
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Leonard Post
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Frank McCormick
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Daniel Y Sze
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tony R Reid.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Reid, T., Freeman, S., Post, L. et al. Effects of Onyx-015 among metastatic colorectal cancer patients that have failed prior treatment with 5-FU/leucovorin. Cancer Gene Ther 12, 673–681 (2005). https://doi.org/10.1038/sj.cgt.7700819

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.cgt.7700819

Keywords

This article is cited by

Search

Advanced search

Quick links